RxTrials Institute Drug Pipeline Alert

Affinium has begun dosing healthy subjects in a Phase I study of AFN-1252 to treat susceptible and resistant staphylococcal infections.

The study will evaluate the safety, tolerability and pharmacokinetics of a single escalating dose of the product.

AFN-1252 is an investigational antibiotic with a high potency against all drug-resistant phenotypes of staphylococci, including hospital- and community-acquired methicillin-resistant Staphylococcus aureus, according to Affinium.